Open AccessResults of treatment of acute myeloid leukemia in central part of Iran
Author(s) -
Farzaneh Ashrafi,
Razieh Shahnazari,
Mojgan Alam Samimi,
Valliollah Mehrzad
Publication year - 2013
Publication title -
advanced biomedical research
Language(s) - English
Resource type - Journals
ISSN - 2277-9175
DOI - 10.4103/2277-9175.114194
Subject(s) - medicine , myeloid leukemia , chemotherapy , complete remission , overall survival , induction chemotherapy , survival rate , leukemia , surgery
Background: Acute myeloid leukemia (AML) is the most common type of leukemia. In this study, outcome of intensive chemotherapy in patients treated in a large urban public university hospital in a developing country was investigated. Materials and Methods: The records of all patients treated for AML with 3 + 7 protocol from 2002 to 2010 were analyzed. Results: Among 95 patients, 34 (35.8%) were female and 61 (64.2%) were male patients. Patients′ median age was 37 years, ranging 15-68 years. Complete remission (CR) was observed in 56 (58.9%) of patients treated with this protocol. Median overall survival was 13 months (95% CI: 8.8-17.1 months). The 1-year AML survival rate was 51%, and 2-year survival rate was 26%.Conclusion: Our study shows that in our center in Iran, CR rates and median overall survival rates after induction chemotherapy are less than developed countries